September 22, 2025|
AI
|2 months agoBreakthrough: Roche Reports Positive Results in Breast Cancer Treatment Trial
Swiss pharmaceutical giant announces significant progress in phase III clinical trials combining giredestrant and everolimus treatments
AI
Generated IllustrationKey Takeaways
AI
- Roche achieved positive results in the Phase III evERA study for breast cancer treatment.
- The treatment targets locally advanced or metastatic estrogen receptor-positive (ER+) and HER2-negative breast cancer.
- The study compared the new combination against the current standard of endocrine therapy plus everolimus.
- Roche is currently running five distinct clinical programs involving giredestrant.
- Data on total patient survival rates is not yet mature.
By The Numbers
Significant
Increase in progression-free survival time
5
Clinical programs
They Said
"Significant increase in the survival time of patients without disease progression."
"The substance is designed to prevent oestrogens from binding to their receptors, thereby interrupting or slowing the progression of cancer cells."